Regulatory Timeline for Orchard Therapeutics’ Leading Gene Therapies | CheckRare.com

Mark Rothera, CEO of Orchard Therapeutics, discusses ex vivo autologous hematopoietic stem cell gene therapies for adenosine deaminase severe combined immunodeficiency (ADA-SCID) and metachromatic leukodystrophy (MLD).

Read the full article here

Related Articles